Clinical trial
A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia…
NCT00202644 · Shire, Industry · Completed
Key facts
| NCT number | NCT00202644 |
|---|---|
| Title | A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients |
| Official title | A Phase IIIb, Randomized, Open Label Study to Compare the Safety, Efficacy and Tolerability of Anagrelide Hydrochloride Versus Hydroxyurea in High-Risk Essential Thrombocythaemia Patients. |
| Lead sponsor | Shire, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Thrombocythemia, Hemorrhagic |
| Intervention type | Drug |
| Interventions | Anagrelide, Hydroxyurea |
| Enrollment | 150 |
| Start date | Jan 13, 2006 |
| Primary completion | Dec 15, 2015 |
| Completion | Dec 15, 2015 |
| First posted | Sep 20, 2005 |
| Last update posted | Jun 2, 2021 |
| Countries | Bulgaria, France, Hungary, Poland, Portugal, Serbia |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: